RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea - Regeneron Pharmaceuticals (NASDAQ:REGN)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!